Remote centres outside Kerala force candidates to drop out of NEET-PG
Many candidates had carefully chosen cities near their residences as preferred centres during the application process. However, many were stunned to be assigned locations hundreds of kilometres away.
'I'm not appearing for the exam this time. I've been allotted a centre in Telangana, and I'm eight months pregnant. The travel and stay costs are too high for me and my family,' said Dr Kavitha (name changed), a candidate from Thiruvananthapuram.
'Other young mothers in my batch are opting out too. We've paid Rs 4,000 for the application, and now we're forced to abandon the attempt.' Surveys conducted by several junior doctor associations revealed that approximately 1,000 applicants from Kerala were given centres outside the state. The uncertainty over exact venue details — only disclosed two days prior to the exam on July 31 — adds to the logistical nightmare.
'If I had received Kollam as my centre, I could reach anywhere nearby without issues. But with a location like Visakhapatnam, I don't even know how close the centre will be to a hotel. How do we plan ahead?' said Dr Ashik Basheer, state president of the General Practitioners Association.
Candidates have also voiced concerns over inflated travel and accommodation prices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
5 minutes ago
- Indian Express
Gujarat to prepare SOPs to stop duplicate, fake medicines from entering state
The Gujarat government, in a statement on Tuesday, said it is in the process of formulating Standard Operating Procedures (SOPs) to enhance detection and seizures of duplicate and fake medicines from entering the state. 'Recently, it came to the notice of the state government that fake medicines are entering (Gujarat). They are being sourced from outside the state and sold in some places inside the state. Gujarat's Food and Drug Control Administration (FDCA) has also taken action by conducting on-site inspections. To make this more stringent and strict, the government will prepare an SOP for the inspection of medicines coming from outside the state into Gujarat,' Health Minister Rushikesh Patel was quoted as saying. The SOPs would make registration of imported medicines mandatory, require registration of transporters carrying medicines and cancellation of licenses of chemists or wholesalers who are caught in such dealing with fake medicines. The SOPs will also require people to strictly follow the Drugs and Cosmetics Act. Besides, expensive and 'fast-moving' medicines will be closely monitored. The state government will also start three new testing labs in addition to the existing NABL-certified laboratory in Vadodara. To intensify on-site testing, 10 sets of state-of-the-art hand-held devices (Raman Spectrometer with Advanced Technology) will be purchased. Further, a flying squad will be formed. Patel added that with the implementation of these SOPs, Gujarat will become the first state in the country to adopt 'zero-tolerance' towards duplicate and fake medicines. 'The government will take intensive action to prevent fake/spurious/counterfeit medicines from outside the state in Gujarat. In the last 4 years, raids were conducted to prevent counterfeit medicines/cosmetics in the state and more than Rs 6 crore (worth of) medicines/cosmetics were seized…about 75 persons/firms were found involved and action was taken against them,' a statement read. Speaking about the type of activities unearthed so far, the statement said, 'In most of these cases, persons who do not have a valid license for buying, selling and storing medicines are involved and investigation has also revealed that in most of the cases, counterfeit medicines come from outside the state.'
Time of India
2 hours ago
- Time of India
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering ( IPO ), which opens for subscription on August 8. The company's maiden public issue will conclude on August 12. The shares are scheduled to be listed on the NSE SME platform on August 18, Medistep Healthcare said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The IPO comprises 37.44 lakh equity shares priced at a fixed Rs 43 per share, aggregating to a total issue size of Rs 16.09 crore. Following the listing, the company is expected to have a market capitalisation of Rs 61.10 crore. The company will utilise the proceeds of the IPO for purchase of plant and machinery for expansion of its existing manufacturing facility, working capital requirements and general corporate purposes. "Proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets," Girdhari Lal Prajapati, Managing Director at Medistep Healthcare, said. Live Events The company is in the business of manufacturing sanitary pads & energy powder, and trading of a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a distribution network. On the financial front, the company recorded revenue from operations of Rs 49.65 crore in FY25, an increase from Rs 39.07 crore in the preceding fiscal. Its profit after tax (PAT) also rose to Rs 4.14 crore in FY25, compared to Rs 3.33 crore in the previous financial year. Fast Track Finsec is the sole lead manager of the public issue while Cameo Corporate Services is the registrar to the issue.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
